Austin Gurney, Ph.D. is a biotech industry veteran with over two decades of experience in the discovery and development of novel therapeutics. In addition to serving as a member of the Board of Directors, he is the founder and principal at Napa Biotechnology Consulting and a member of the Board of AntlerA Therapeutics.
Prior to his current roles, Austin was Chief Scientific Officer, Senior Vice President of Research at OncoMed Pharmaceuticals where he held various management roles of increasing responsibility between 2004 and 2017. During this time, he and his teams discovered and developed five first-in-class therapeutic agents. Prior to OncoMed, Austin worked at Genentech where his research led to the discovery of several growth factors and cytokines. He has authored or co-authored more than 60 published scientific papers and is listed as an inventor on over 600 patents related to therapeutic applications in immunology and cancer.
Austin holds a B.S. in Biology from Rensselaer Polytechnic Institute. He received his Ph.D. in Biochemistry and Molecular Biology from Case Western Reserve University.